What changed for Castleman Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Castleman Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials on record 32 to 34 (+2)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Castleman Disease in July 2026. Voxsanity tracks 1 PBS-subsidised medicine for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Castleman Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04585893 · results posted 11 September 2025
According to the results reported on ClinicalTrials.gov, a total of 15 people took part in this trial — 9 classified as "high-risk" and 6 classified as "low-risk." The trial was studying a treatment approach for Multicentric Castleman disease (MCD), a rare condition affecting the lymph nodes, in Malawi. The trial divided participants into two groups based on their risk level and gave each group a different treatment suited to their risk category. Of the 15 who started, 14 completed the study (8 high-risk and 6 low-risk), with one high-risk participant not completing it. The reported data show...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT01400503 · results posted 29 March 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 participants, all of whom received a medicine called siltuximab. The trial was a long-term safety extension study, meaning its main purpose was to track unwanted medical events (called adverse events) that occurred while participants were receiving the treatment. The reported data shows that none of the 60 participants were recorded as having "completed" the study in the usual sense — all 60 were listed under "not completed," which may reflect the nature of a long-term extension study, though no further explanation...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT01024036 · results posted 20 August 2014
According to the results reported on ClinicalTrials.gov, this trial looked at a condition called multicentric Castleman's disease, which is a rare disorder affecting the lymph nodes. A total of 79 people took part — 53 received a medicine called siltuximab alongside best supportive care (standard care aimed at managing symptoms), and 26 received a placebo (a dummy treatment) alongside best supportive care. The trial's main goal was to measure how many participants had a meaningful and lasting shrinkage of their disease along with an improvement in symptoms, sustained for at least 18 weeks. Th...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a moderate amount of public research investment is currently being directed toward Castleman Disease, and that level has remained broadly steady from year to year. For patients, this suggests the condition is on the radar of publicly funded researchers, without any dramatic surge or sharp decline in attention. Steady funding at a moderate level generally means that s...
See the full Castleman Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.